Clinical Rundown: 3 Hot Topic Sessions on ASCVD Risk Reduction

A showcase of hot topics in the management of elevated LDL-C and triglycerides across the spectrum of disease.

Live Meeting
2.00 available credits
Information
November 14, 2021
06:00 PM - 08:30 PM EST
Westin Boston Seaport
Marina Ballroom 1 & 2, Lobby Level, 425 Summer Street, Boston, Massachusetts, United States
Clinical Rundown: 3 Hot Topic Sessions on ASCVD Risk Reduction
Choose a format
Details
Presenters
Comments
  • Overview

    This activity employs unique, innovative features to provide excellent clinical content and a strong learning environment for healthcare professionals who treat patients with or at risk of ASCVD. In the first session of this symposium, the focus is on omega-3 fatty acids. The second session focuses on the clinical management of LDL-lowering therapies and provides insight on managing patients with hypertriglyceridemia. The third session features rapid-fire case discussions to put the previous content into context and challenge the attendees’ patient management skills. The format is similar to the scientific sessions where topics in a themed session are presented and discussed in rapid succession.

  • Program Schedule*

    6:00 pm-6:30 pm

    6:30 pm–6:35 pm

    Registration & Buffet

    Welcome, Introductions, Program Overview
    Lawrence A. Leiter, MD
    Peter Libby, MD
    Program Co-Chairs

    Session 1

    6:35 pm–7:25 pm

    Hot Topics in Omega-3 Fatty Acids
    Peter Libby, MD (Chair)

    Reconciling the Outcomes of REDUCE-IT and STRENGTH: Was It the Drug, the Dose, or the Study?
    Deepak L. Bhatt, MD

    EPA and DHA: Basic Evidence on What’s Similar, What’s Different
    R. Preston Mason, PhD

    Plaque Regression and OM-3s: What Does Imaging Tell Us?
    Deepak L. Bhatt, MD

    Evidence and Insights on O3FA Differential Cardiovascular Effects
    R. Preston Mason, PhD

    Panel Discussion

    Session 2

    7:25 pm–8:05 pm

    Hot Topics in ASCVD Risk Reduction
    Lawrence A. Leiter, MD (Chair)

    Scientific Statements, Guidelines, and Recommendations – What’s Similar, What’s Different
    Kausik K. Ray, MBChB, MD

    TG Level: Is It a Biomarker, Risk Factor, or Treatment Target?
    Christie M. Ballantyne, MD

    Achieving Desired Lipid Levels with Current Treatment Options
    Kausik K. Ray, MBChB, MD

    New Options and Methods to Manage Statin Intolerance

    Christie M. Ballantyne, MD

    Panel Discussion

    Session 3

    8:05 pm –8:30 pm






    Attendee Countdown: You Judge the Case
    Lawrence A. Leiter, MD
    Peter Libby, MD
    Co-Chairs

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC – Co-Chair
    Division of Endocrinology and Metabolism
    St. Michael's Hospital
    Professor of Medicine and Nutritional Sciences
    University of Toronto
    Toronto, Ontario, Canada
    Consulting Fees: Amarin, Esperion
    Speakers Bureau: Amarin

    Peter Libby, MD, FACC – Co-Chair
    Cardiovascular Medicine Specialist
    Mallinckrodt Professor of Medicine
    Brigham and Women's Hospital
    Harvard Medical School
    Boston, MA
    Consultant/Clinical Trials (unpaid): Esperion Therapeutics

    Christie M. Ballantyne, MD
    Chief, Sections of Cardiology and Cardiovascular Research
    Professor and Vice Chair of Research
    J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
    Department of Medicine
    Director, Center for Cardiometabolic Disease Prevention
    Baylor College of Medicine
    Houston, TX

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
    Executive Director of Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor of Medicine
    Harvard Medical School
    Boston, MA
    Consulting Fees: Amarin

    R. Preston Mason, PhD
    Cardiovascular Division
    Brigham and Women’s Hospital
    Harvard Medical School
    Boston, MA
    Scientific Director and Founder, Elucida Research
    Beverly, MA
    Contract Research & Consulting: Amarin

    Kausik K. Ray, MBChB, MD, MPhil, FRCP
    Professor of Public Health
    Director, Imperial Centre for CVD Prevention
    Deputy Director, Imperial Clinical Trials Unit
    Head, Commercial Trials
    Consultant Cardiologist
    Imperial College London
    London, United Kingdom
    Consulting Fees: Esperion

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett, has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Anna Trentini has nothing to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss recent omega-3 fatty acid outcomes trial results and their clinical implications in reducing ASCVD events
    • Describe the clinical utility of statin-adjunct therapies for ASCVD event reduction
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk

  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, lipidologists, internists, diabetologists, and endocrinologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative  is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by independent educational grants from Amarin Pharma, Inc., and Esperion Therapeutics.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact Anna Trentini prior to the live event at atrentini@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
  • Overview

    This activity employs unique, innovative features to provide excellent clinical content and a strong learning environment for healthcare professionals who treat patients with or at risk of ASCVD. In the first session of this symposium, the focus is on omega-3 fatty acids. The second session focuses on the clinical management of LDL-lowering therapies and provides insight on managing patients with hypertriglyceridemia. The third session features rapid-fire case discussions to put the previous content into context and challenge the attendees’ patient management skills. The format is similar to the scientific sessions where topics in a themed session are presented and discussed in rapid succession.

  • Program Schedule*

    6:00 pm-6:30 pm

    6:30 pm–6:35 pm

    Registration & Buffet

    Welcome, Introductions, Program Overview
    Lawrence A. Leiter, MD
    Peter Libby, MD
    Program Co-Chairs

    Session 1

    6:35 pm–7:25 pm

    Hot Topics in Omega-3 Fatty Acids
    Peter Libby, MD (Chair)

    Reconciling the Outcomes of REDUCE-IT and STRENGTH: Was It the Drug, the Dose, or the Study?
    Deepak L. Bhatt, MD

    EPA and DHA: Basic Evidence on What’s Similar, What’s Different
    R. Preston Mason, PhD

    Plaque Regression and OM-3s: What Does Imaging Tell Us?
    Deepak L. Bhatt, MD

    Evidence and Insights on O3FA Differential Cardiovascular Effects
    R. Preston Mason, PhD

    Panel Discussion

    Session 2

    7:25 pm–8:05 pm

    Hot Topics in ASCVD Risk Reduction
    Lawrence A. Leiter, MD (Chair)

    Scientific Statements, Guidelines, and Recommendations – What’s Similar, What’s Different
    Kausik K. Ray, MBChB, MD

    TG Level: Is It a Biomarker, Risk Factor, or Treatment Target?
    Christie M. Ballantyne, MD

    Achieving Desired Lipid Levels with Current Treatment Options
    Kausik K. Ray, MBChB, MD

    New Options and Methods to Manage Statin Intolerance

    Christie M. Ballantyne, MD

    Panel Discussion

    Session 3

    8:05 pm –8:30 pm






    Attendee Countdown: You Judge the Case
    Lawrence A. Leiter, MD
    Peter Libby, MD
    Co-Chairs

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Lawrence A. Leiter, MD, FRCPC, FACP, FACE, FAHA, FACC – Co-Chair
    Division of Endocrinology and Metabolism
    St. Michael's Hospital
    Professor of Medicine and Nutritional Sciences
    University of Toronto
    Toronto, Ontario, Canada
    Consulting Fees: Amarin, Esperion
    Speakers Bureau: Amarin

    Peter Libby, MD, FACC – Co-Chair
    Cardiovascular Medicine Specialist
    Mallinckrodt Professor of Medicine
    Brigham and Women's Hospital
    Harvard Medical School
    Boston, MA
    Consultant/Clinical Trials (unpaid): Esperion Therapeutics

    Christie M. Ballantyne, MD
    Chief, Sections of Cardiology and Cardiovascular Research
    Professor and Vice Chair of Research
    J.S. Abercrombie Chair, Atherosclerosis & Lipoprotein Research
    Department of Medicine
    Director, Center for Cardiometabolic Disease Prevention
    Baylor College of Medicine
    Houston, TX

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
    Executive Director of Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center
    Professor of Medicine
    Harvard Medical School
    Boston, MA
    Consulting Fees: Amarin

    R. Preston Mason, PhD
    Cardiovascular Division
    Brigham and Women’s Hospital
    Harvard Medical School
    Boston, MA
    Scientific Director and Founder, Elucida Research
    Beverly, MA
    Contract Research & Consulting: Amarin

    Kausik K. Ray, MBChB, MD, MPhil, FRCP
    Professor of Public Health
    Director, Imperial Centre for CVD Prevention
    Deputy Director, Imperial Clinical Trials Unit
    Head, Commercial Trials
    Consultant Cardiologist
    Imperial College London
    London, United Kingdom
    Consulting Fees: Esperion

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett, has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Anna Trentini has nothing to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss recent omega-3 fatty acid outcomes trial results and their clinical implications in reducing ASCVD events
    • Describe the clinical utility of statin-adjunct therapies for ASCVD event reduction
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk

  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, lipidologists, internists, diabetologists, and endocrinologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative  is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by independent educational grants from Amarin Pharma, Inc., and Esperion Therapeutics.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact Anna Trentini prior to the live event at atrentini@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free